Pregnancy Outcomes in Women with Recurrent Pregnancy Loss According to Endometrial CD138-Positive Plasma Cell Counts Used for Chronic Endometritis Diagnosis: A Cohort Study
8 affiliations
- 1Reproduction and Endometriosis Treatment Ward, Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences, 60-701 Poznan, Poland
- 2Department of Clinical Pathology, Poznan University of Medical Sciences, 60-701 Poznan, Poland
- 3Student Scientific Association of Department of Reproduction and Gynecology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- 4Greater Poland Center of Digital Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland
- 5Department of Reproduction, Chair of Reproduction and Perinatal Medicine, Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences, 60-701 Poznan, Poland
- 6The Recurrent Pregnancy Loss Unit, The Fertility Clinic, Copenhagen University Hospitals Rigshospitalet and Hvidovre, The Capital Region of Denmark, 2100 Copenhagen, Denmark
- 7The Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark
- 8Department of Reproduction and Gynecology, Gynecological Obstetric Clinical Hospital of Poznan University of Medical Sciences, 60-701 Poznan, Poland
Abstract
Background: Chronic endometritis (CE), defined histologically by plasma cell infiltration of the endometrial stroma, has been proposed as a modifiable contributor to recurrent pregnancy loss (RPL). However, most existing evidence on the reproductive impact of CE derives from patients with recurrent implantation failure (RIF) undergoing assisted reproductive technology (ART), and diagnostic thresholds for CE remain inconsistent across studies. Objective: To evaluate whether the presence and quantity of CD138+ plasma cells on endometrial biopsy are associated with the outcome of a subsequent spontaneous pregnancy in patients with RPL, and to assess whether this association is sensitive to the diagnostic threshold applied. Methods: In this prospective cohort study, women with a history of two or more pregnancy losses before 22 weeks of gestation who underwent diagnostic hysteroscopy with endometrial biopsy between 2021 and 2024 were included. Endometrial samples were immunohistochemically stained for CD138 and evaluated by two independent pathologists. Pregnancy outcomes were obtained via a patient-reported survey administered in 2025 (follow-up of up to two years after hysteroscopy) and were analyzed in women who conceived and had an available histopathology result, according to plasma cell count using three classification schemes: presence versus absence (≥1 vs. 0 cells/10 HPF), a higher threshold (≥2 vs. ≤1 cells/10 HPF), and a three-tier stratification (0, 1, ≥2 cells/10 HPF). Results: Of 100 women recruited, 95 responded to the survey, 74 conceived, and 70 had a histopathology result and were analyzed (43 with 0 and 27 with ≥1 CD138+ plasma cells/10 HPF). Live birth occurred in 21/43 (48.8%) women with 0 plasma cells and in 10/27 (37.0%) with ≥1 plasma cell/10 HPF (OR 0.62, 95% CI 0.23–1.65; p = 0.333), and in 25/51 (49.0%) women with ≤1 and 6/19 (31.6%) with ≥2 cells/10 HPF (OR 0.48, 95% CI 0.16–1.46; p = 0.191). In the three-tier comparison, live birth rates were 48.8% (0 cells), 50.0% (1 cell; n = 8) and 31.6% (≥2 cells) (p = 0.425). None of the differences was statistically significant, but the study was small and the confidence intervals were wide. Conclusions: In this small cohort of women with RPL who conceived spontaneously, live birth rates were numerically lower in women with higher CD138+ plasma cell counts, but the differences were not statistically significant at any threshold tested. The findings are exploratory and do not exclude a clinically relevant association; larger prospective studies are needed.
Related
- Fertility preservation with successful pregnancy outcome in a young patient with endometrial cancer
- A perfusable first-generation endometrial microvascular model to study human spiral artery remodeling in pregnancy.
- Serum Folate and Plasma Homocysteine According to MTHFR C677T Genotype and Folic Acid Supplementation in Japanese Women Preparing for Pregnancy: A Cross-Sectional Study
- Recurrent venous thromboembolism despite natural cycle frozen embryo transfer in a woman with a history of pregnancy-related venous thromboembolism: A case report.
- Non-criteria antiphospholipid antibodies and pregnancy outcomes in recurrent pregnancy loss patients
BibTeX
@article{klimaszyk2026pregnancy,
title = {{Pregnancy Outcomes in Women with Recurrent Pregnancy Loss According to Endometrial CD138-Positive Plasma Cell Counts Used for Chronic Endometritis Diagnosis: A Cohort Study}},
author = {Katarzyna Klimaszyk and Katarzyna Bednarek Rajewska and Anna Prościńska and Marta Zakrzewska and Maurycy Jankowski and Ewa Wender Ożegowska and Henriette Svarre Nielsen and Małgorzata Kędzia},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15228783},
url = {https://www.mdpi.com/2077-0383/15/22/8783},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pregnancy Outcomes in Women with Recurrent Pregnancy Loss According to Endometrial CD138-Positive Plasma Cell Counts Used for Chronic Endometritis Diagnosis: A Cohort Study
AU - Katarzyna Klimaszyk
AU - Katarzyna Bednarek Rajewska
AU - Anna Prościńska
AU - Marta Zakrzewska
AU - Maurycy Jankowski
AU - Ewa Wender Ożegowska
AU - Henriette Svarre Nielsen
AU - Małgorzata Kędzia
PY - 2026
DA - 2026/11/10
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15228783
UR - https://www.mdpi.com/2077-0383/15/22/8783
AB - Background: Chronic endometritis (CE), defined histologically by plasma cell infiltration of the endometrial stroma, has been proposed as a modifiable contributor to recurrent pregnancy loss (RPL). However, most existing evidence on the reproductive impact of CE derives from patients with recurrent implantation failure (RIF) undergoing assisted reproductive technology (ART), and diagnostic thresholds for CE remain inconsistent across studies. Objective: To evaluate whether the presence and quantity of CD138+ plasma cells on endometrial biopsy are associated with the outcome of a subsequent spontaneous pregnancy in patients with RPL, and to assess whether this association is sensitive to the diagnostic threshold applied. Methods: In this prospective cohort study, women with a history of two or more pregnancy losses before 22 weeks of gestation who underwent diagnostic hysteroscopy with endometrial biopsy between 2021 and 2024 were included. Endometrial samples were immunohistochemically stained for CD138 and evaluated by two independent pathologists. Pregnancy outcomes were obtained via a patient-reported survey administered in 2025 (follow-up of up to two years after hysteroscopy) and were analyzed in women who conceived and had an available histopathology result, according to plasma cell count using three classification schemes: presence versus absence (≥1 vs. 0 cells/10 HPF), a higher threshold (≥2 vs. ≤1 cells/10 HPF), and a three-tier stratification (0, 1, ≥2 cells/10 HPF). Results: Of 100 women recruited, 95 responded to the survey, 74 conceived, and 70 had a histopathology result and were analyzed (43 with 0 and 27 with ≥1 CD138+ plasma cells/10 HPF). Live birth occurred in 21/43 (48.8%) women with 0 plasma cells and in 10/27 (37.0%) with ≥1 plasma cell/10 HPF (OR 0.62, 95% CI 0.23–1.65; p = 0.333), and in 25/51 (49.0%) women with ≤1 and 6/19 (31.6%) with ≥2 cells/10 HPF (OR 0.48, 95% CI 0.16–1.46; p = 0.191). In the three-tier comparison, live birth rates were 48.8% (0 cells), 50.0% (1 cell; n = 8) and 31.6% (≥2 cells) (p = 0.425). None of the differences was statistically significant, but the study was small and the confidence intervals were wide. Conclusions: In this small cohort of women with RPL who conceived spontaneously, live birth rates were numerically lower in women with higher CD138+ plasma cell counts, but the differences were not statistically significant at any threshold tested. The findings are exploratory and do not exclude a clinically relevant association; larger prospective studies are needed.
SN - 2077-0383
ER -